Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
883.2 DKK | +0.07% | +1.16% | +26.51% |
05-10 | Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows | RE |
05-10 | India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says | RE |
Sales 2024 * | 289B 41.75B 3,335B | Sales 2025 * | 348B 50.27B 4,015B | Capitalization | 3,935B 568B 45,364B |
---|---|---|---|---|---|
Net income 2024 * | 104B 15.01B 1,199B | Net income 2025 * | 126B 18.22B 1,455B | EV / Sales 2024 * | 13.7 x |
Net Debt 2024 * | 13.34B 1.93B 154B | Net cash position 2025 * | 12.63B 1.82B 146B | EV / Sales 2025 * | 11.3 x |
P/E ratio 2024 * |
38.1
x | P/E ratio 2025 * |
31.4
x | Employees | 66,015 |
Yield 2024 * |
1.33% | Yield 2025 * |
1.59% | Free-Float | 70.17% |
Latest transcript on Novo Nordisk A/S
1 day | +0.07% | ||
1 week | +1.16% | ||
Current month | -2.15% | ||
1 month | +2.97% | ||
3 months | +6.17% | ||
6 months | +26.99% | ||
Current year | +26.51% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 31/12/90 | |
Director of Finance/CFO | 53 | 31/12/98 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 18/03/15 |
Helge Lund
CHM | Chairman | 61 | 22/03/17 |
Martin MacKay
BRD | Director/Board Member | 68 | 28/02/18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
21.31% | 0 M€ | +16.95% | ||
10.45% | 0 M€ | +12.11% | ||
5.40% | 0 M€ | +6.32% | - | |
4.67% | 88 M€ | +10.37% | - |
Date | Price | Change | Volume |
---|---|---|---|
08/05/24 | 883.2 | +0.07% | 2,737,492 |
07/05/24 | 882.6 | +3.66% | 9,320,634 |
06/05/24 | 851.4 | +0.09% | 1,874,622 |
Delayed Quote Nasdaq Copenhagen, May 08, 2024 at 03:59 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.51% | 568B | |
+30.38% | 684B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B | |
-2.71% | 159B |
- Stock Market
- Equities
- NOVO B Stock